Why is it important—the mandate, in fact—to diagnose FD, and what is the current evidence and/or expert consensus about the use of either chaperone therapy with migalastat or ERT to mitigate progression of FD in the kidney and in other target organs?

Why is it important—the mandate, in fact—to diagnose FD, and what is the current evidence and/or expert consensus about the use of either chaperone therapy with migalastat or ERT to mitigate progression of FD in the kidney and in other target organs?

CLICK HERE FOR CME CREDIT

Why is it important—the mandate, in fact—to diagnose FD, and what is the current evidence and/or expert consensus about the use of either chaperone therapy with migalastat or ERT to mitigate progression of FD in the kidney and in other target organs?

Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

Alberto Ortiz, MD

Alberto Ortiz, MD

Chief of Nephrology and Hypertension
Renal Unit, IIS-Fundacio?n Jime?nez Di?az
Universidad Auto?noma de Madrid, FRIAT
Madrid, Spain